Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Apellis Pharmaceuticals, Inc.
  6. News
  7. Summary
    APLS   US03753U1060

APELLIS PHARMACEUTICALS, INC.

(APLS)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-02 pm EST
56.73 USD   +3.11%
01/25Insider Sell: Apellis Pharmaceuticals
MT
01/09Transcript : Apellis Pharmaceuticals, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 09:00 AM
CI
01/09Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Credit Suisse Lowers Apellis Pharmaceuticals' Price Target to $43 From $45, Keeps Neutral Rating

11/08/2022 | 09:46am EST
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about APELLIS PHARMACEUTICALS, INC.
01/25Insider Sell: Apellis Pharmaceuticals
MT
01/09Transcript : Apellis Pharmaceuticals, Inc. Presents at 41st Annual J.P. Morga..
CI
01/09Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635
AQ
01/06Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
GL
01/06Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
AQ
01/05Apellis Pharmaceuticals, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
01/05Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
GL
01/05Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
GL
01/05Apellis Appoints Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
CI
01/04North American Morning Briefing: Futures Rise -2-
DJ
More news
Analyst Recommendations on APELLIS PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 77,4 M - -
Net income 2022 -660 M - -
Net cash 2022 391 M - -
P/E ratio 2022 -9,04x
Yield 2022 -
Capitalization 6 267 M 6 267 M -
EV / Sales 2022 75,9x
EV / Sales 2023 30,1x
Nbr of Employees 476
Free-Float 84,6%
Chart APELLIS PHARMACEUTICALS, INC.
Duration : Period :
Apellis Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APELLIS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 56,73 $
Average target price 74,69 $
Spread / Average Target 31,7%
EPS Revisions
Managers and Directors
Cedric Francois President, Chief Executive Officer & Director
Timothy Eugene Sullivan Chief Financial Officer & Treasurer
Lok Chung Chan Chairman
Pascal Deschatelets Chief Scientific Officer
Nur Nicholson Chief Technical Operations Officer
Sector and Competitors
1st jan.Capi. (M$)
APELLIS PHARMACEUTICALS, INC.6.40%6 078
CSL LIMITED4.78%102 879
SAMSUNG BIOLOGICS CO.,LTD.-2.07%46 610
BIOGEN INC.5.05%41 991
WUXI BIOLOGICS (CAYMAN) INC.12.03%36 129
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.10.37%23 006